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Abstract
Background: ClC-Kb and ClC-Ka are homologous chloride channels that facilitate chloride homeostasis in the kidney and
inner ear. Disruption of ClC-Kb leads to Bartter’s Syndrome, a kidney disease. A point mutation in ClC-Kb, R538P, linked to
Bartter’s Syndrome and located in the C-terminal cytoplasmic domain was hypothesized to alter electrophysiological
properties due to its proximity to an important membrane-embedded helix.
Methodology/Principal Findings: Two-electrode voltage clamp experiments were used to examine the electrophysiological
properties of the mutation R538P in both ClC-Kb and ClC-Ka. R538P selectively abolishes extracellular calcium activation of
ClC-Kb but not ClC-Ka. In attempting to determine the reason for this specificity, we hypothesized that the ClC-Kb C-
terminal domain had either a different oligomeric status or dimerization interface than that of ClC-Ka, for which a crystal
structure has been published. We purified a recombinant protein corresponding to the ClC-Kb C-terminal domain and used
multi-angle light scattering together with a cysteine-crosslinking approach to show that the dimerization interface is
conserved between the ClC-Kb and ClC-Ka C-terminal domains, despite the fact that there are several differences in the
amino acids that occur at this interface.
Conclusions: The R538P mutation in ClC-Kb, which leads to Bartter’s Syndrome, abolishes calcium activation of the channel.
This suggests that a significant conformational change – ranging from the cytoplasmic side of the protein to the
extracellular side of the protein – is involved in the Ca
2+-activation process for ClC-Kb, and shows that the cytoplasmic
domain is important for the channel’s electrophysiological properties. In the highly similar ClC-Ka (90% identical), the R538P
mutation does not affect activation by extracellular Ca
2+. This selective outcome indicates that ClC-Ka and ClC-Kb differ in
how conformational changes are translated to the extracellular domain, despite the fact that the cytoplasmic domains share
the same quaternary structure.
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Introduction
Members of the CLC family of chloride channels and
transporters are ubiquitously expressed and serve a variety of
physiological functions [1,2]. Mutations in human CLCs give rise
to a number of diseases including Bartter’s syndrome (ClC-Kb
[3–7]), myotonia congenita (ClC-1 [8–11]), epilepsy (ClC-2 [12–
14]), Dent’s disease (ClC-5 [15–19]), and osteopetrosis (ClC-7
[20]). ClC-Kb is expressed in the thick ascending limb of the
kidney, where it facilitates chloride reabsorption [21]. ClC-Kb,
together with the nearly identical homolog ClC-Ka, serves a
similar role in chloride homeostasis in the stria vascularis of the
inner ear [22].
Eukaryotic CLC proteins consist of two domains: a membrane
domain that forms the chloride-selective permeation pathway and
a C-terminal cytoplasmic domain. (Figure 1) [1,2,23]. In contrast
to the relatively much-studied permeation pathway, the functional
role of CLC cytoplasmic domains remains less well understood.
Even so, their physiological importance is underscored by the large
number of truncations and point mutations that result in disease
[24]. While disruption of the cytoplasmic domain can interfere
with folding and/or trafficking and thus result in a decrease of
functional protein at the plasma membrane [20,24–31], there are
clues that the cytoplasmic domains are also important for
electrophysiological function. This has most clearly been shown
for the skeletal muscle homologs ClC-0 and ClC-1. In ClC-0,
mutations in the cytoplasmic domain affect the ‘‘slow’’ cooperative
gating [24,28,32]. In ClC-1, point mutations in the cytoplasmic
domains cause shifts in voltage-dependent gating that are linked to
dominantly inherited myotonia [8,33]. Disease-causing cytoplas-
mic domain point mutations are also found in several other
homologs; however, in these cases, the electrophysiological effects
of the mutations are either controversial (ClC-2) [12,34] or not yet
reported (ClC-6, ClC-7, and ClC-Kb) [35–37].
Here we study the point mutation R538P, which occurs in the
C-terminal cytoplasmic domain of ClC-Kb and causes Bartter’s
Syndrome [37]. R538 is located in the linker region between the
membrane domain and the cytoplasmic domain (Figure 1A). We
show that this mutation changes gating at hyperpolarized
membrane potentials, alters selectivity and removes activation
induced by extracellular calcium. Thus, the mutation of a single
amino acid in the cytoplasmic domain causes a long range
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domain of ClC-Kb. In the homologous ClC-Ka (90% identical),
the R538P mutation does not yield the same changes in gating or
calcium activation. This surprising difference indicates that ClC-
Ka and ClC-Kb differ either structurally or in how conformational
changes are translated to the extracellular domain.
The C-terminal domains of CLCs contain a pair of conserved
protein motifs referred to as cystathionine beta-synthase domains
(CBSDs) [38]. CBSDs are present in a diverse array of proteins,
where they are independent domains that play roles in the
regulation of the core domain’s catalytic activity [39]. In
cystathionine beta-synthase, mutations in the CBSDs eliminate
the protein’s ability to be activated by endogenous ligand and lead
to the disease homocystinuria, a defect in the methionine
metabolism pathway [40]. In AMP-activated protein kinase,
mutations in the CBSDs of the gamma subunit result in familial
hypertrophic cadiomyopathy, presumably because altered regula-
tion of the other subunits [41].
The structures of two human CLC C-terminal cytoplasmic
domains, ClC-Ka [42] and ClC-5 [43], have been determined.
Both of these constructs form dimers, with the intermolecular
interface occurring between CBSD2 of each subunit (Figure 1B).
This architecture is preserved in solution, as illustrated by cross-
linking studies on the ClC-Ka C-terminal domains [42]. In
contrast, a cytoplasmic domain construct from the Torpedo
homolog ClC-0 crystallizes as a monomer [44]. However, the
domain in solution is a dimer, and cross-linking studies on full-
length ClC-0 indicates that the dimer interface is similar to that for
ClC-Ka and ClC-5 [44].
Despite the similarities between the CBSD structures described
above, there is some plasticity in the oligomeric architecture of
CBSDs. In IMPDH, for example, the structure of the full-length
protein reveals a monomeric CBSD [45]. In the prokaryotic
protein TM0935, a protein comprised entirely of CBSDs, the
crystal structure (PDB ID 1O50) reveals a dimeric protein that has
a completely different intermolecular interface than that observed
in ClC-Ka and ClC-5 [52] (Figure 1C). This interface is also
observed in a recombinant protein consisting of two of the CBSDs
of the eukaryotic protein AMPK [46], and in TA0289, a
Thermoplasma acidophilum protein containing a C-terminus Zn
ribbon domain along with its CBSD [47].
Because ClC-Kb differs from ClC-Ka in some of the key
residues occurring at the dimer interface, we hypothesized that the
differences in the effect of R583P on ClC-Ka and ClC-Kb
function may reflect differences in the oligomeric architecture of
the cytoplasmic domains. On testing this hypothesis, we found that
the cytoplasmic domain of ClC-Kb is dimeric and that the dimer
interface adopted is similar to that observed in the structure of the
C-terminal domain of ClC-Ka.
Results
Characterization of the R538P mutation in ClC-Kb
In ClC-Kb, R538 is located after the last membrane helix
(helix-R) immediately preceding CBSD1 (Figure 1). Since helix-R
lines the chloride permeation pathway [48,49] and extends into
the cytoplasm, we hypothesized that the R538P mutation could
alter helix orientation, thus potentially affecting both gating and
permeation. Indeed, we observe alterations in both properties.
Wild-type ClC-Kb has a linear steady-state voltage dependence
with only slight activation and inactivation at depolarized and
hyperpolarized potentials respectively (Figure 2A, C). In contrast,
ClC-Kb-R538P is slightly inwardly rectifying and exhibits
activation at hyperpolarized potentials (Figure 2B, C). To test
whether there are any alterations in the permeation pathway of
ClC-Kb-R538P channels, we assessed the relative permeability of
different anions. Wild-type ClC-Kb channels show a selectivity
sequence of Cl
2.Br
2=I
2, whereas ClC-Kb-R538P shows a
slight but significant increase in the relative permeability of
bromide (Figure 2D–F).
Two characteristic features of ClC-K channels are their
activation by extracellular alkalinization and by extracellular
Ca
2+ [21,50,51]. No change was observed in the pH dependence
of ClC-Kb-R538P relative to wild type channels (data not shown).
In contrast, extracellular activation by Ca
2+ was abolished: wild
type ClC-Kb exhibits a ,2-fold activation when extracellular
Ca
2+ is raised from 0.1 to 10 mM calcium, whereas no significant
activation is seen with ClC-Kb-R538P under the same conditions
(Figure 3).
Figure 1. CLC domain architecture and the location of R538. (A)
Homology model of ClC-Kb using ClC-ec1 (1OTS) as a template for the
membranedomain andtheClC-Ka C-terminal domain structure (2PFI)as a
template for the cytoplasmic domain. Subunit A (grey) has several amino
acids removed to show the ion coordination of chloride by Y520 (in
spacefill), located on helix-R. R538 is located in the cytoplasmic-domain
loop (red) that connects helix-R to CBSD1. (B) Structure of the ClC-Ka C-
terminal domain (2PFI) highlighting the different CBSDs. Subunit 1 has
CBSD1 in blue and CBSD2 in cyan; subunit 2 has CBSD1 in red and CBSD2
in violet. (C) Structure of TM0935 (1OTS) with the color scheme as in B. All
cartoons were generated in PyMol (http://www.pymol.org).
doi:10.1371/journal.pone.0002746.g001
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Since ClC-Kb shares a high degree of sequence identity with
ClC-Ka (,90% identity), we investigated whether the R538P
mutation in ClC-Ka would induce similar changes in voltage
dependence, selectivity and calcium activation. Surprisingly, we
found only subtle changes: selectivity measurements showed a
slight decrease in relative iodide permeation, while voltage- and
Ca
2+ -activation were unaffected (Figure 4). These results suggest
that despite the overall similarity between ClC-Ka and ClC-Kb,
the properties imparted to the pore by the cytoplasmic domains
are quite different.
Analysis of the ClC-Kb cytoplasmic domain
We hypothesized that the differences in the functional effects of
the mutation in ClC-Ka and ClC-Kb might be due to a difference
between the two C-terminal cytoplasmic domains. The cytoplas-
mic domain of ClC-Kb is over 90% identical to the cytoplasmic
domain of ClC-Ka, for which a crystal structure has been
determined [42], and therefore the structures are likely to be
identical. However, when the residues that differ between the two
homologs are mapped onto the ClC-Ka crystal structure, it is
surprising to note that two of these residues occur at the dimer
interface, at the core of the protein. In particular, amino acid 636
is a phenylalanine in ClC-Ka which when mutated removes ClC-
Ka cytoplasmic domain dimerization [42]; in ClC-Kb, amino acid
636 is a non-hydrophobic serine (Figure 5A). This suggests the
possibility that the ClC-Kb C-terminal domain may not dimerize
or dimerize differently than ClC-Ka. We tested this hypothesis by
determining the oligomeric status of a recombinant protein
corresponding to the C-terminal domain of ClC-Kb. Gel-filtration
chromatography and multi-angle light-scattering both indicate
that this protein, like that of the C-terminal domain of ClC-Ka, is
a dimer in solution (Figure 5B).
Following this observation, we next sought to compare the
dimerization interfaces of the ClC-Ka and Kb cytoplasmic
domains. In contrast to the dimerization interface seen in the
ClC-Ka crystal structure, a second dimerization interface has been
observed in other CBSD-containing proteins, TM0935, TA0289,
and AMPK [46,47,52]. A number of the residues differing
between ClC-Ka and ClC-Kb localize to the helices that form this
interface (Figure 6A), which led us to question whether the ClC-
Kb cytoplasmic domain might form an interface similar to that
observed in TM0935 rather than ClC-Ka. To evaluate the ClC-
Kb dimer interface, we used a cysteine-crosslinking strategy. In the
ClC-Ka C-terminal domain structure, leucine 650 of one subunit
is in close proximity (,5A ˚) to the same residue in the other
subunit, and constructs with the L650C mutation spontaneously
cross-link in solution [42]. In the ClC-Kb C-terminal domain
protein with the L650C mutation, spontaneous cross-linking in
solution is also observed (Figure 6D). Thus, the interface seen in
the ClC-Ka C-terminal domain crystal structure likely occurs in
ClC-Kb as well.
While the ClC-Kb-L650C crosslink suggests a dimer interface
similar to that observed in ClC-Ka, it does not rule out that in
ClC-Kb there is an equilibrium between two dimerization
conformations: one corresponding to the ClC-Ka dimer and the
other to the TM0935 dimer. Such an equilibrium would suggest a
‘‘subunit swapping’’ mechanism, where the cytoplasmic domain
interconverts between conformations with different dimerization
interfaces. To assess this possibility, we designed two pairs of
Figure 2. Gating and selectivity of ClC-Kb-R538P. Two-electrode voltage clamp recordings of (A) wild type and (B) R538P ClC-Kb channels.
Currents are in response to a 200-ms prepulse to +60 mV followed by 500-ms test pulses ranging from +60 mV to 2140 mV in 220 mV decrements.
(C) Steady-state currents at the different voltages were normalized to the current value at +60 mV for wild type (filled squares) and R538P (open
squares). Error bars are s.e.m. with n=8 (WT) and n=6 (R538P). Error bars smaller than the symbols are not shown. Representative steady state I–V
curves for (D) wild type and (E) R538P channels in the presence of chloride (filled squares), bromide (open squares), or iodide (open diamonds). (F)
Permeability ratios relative to chloride for wild type (filled bars) and R538P (open bars). The bromide/chloride permeability ratio of R538P is
statistically different from that of wild type (p,0.0005, n=5).
doi:10.1371/journal.pone.0002746.g002
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cysteine cross-links based on the TM0935 structure but not on the
ClC-Ka structure (Figure 6B, C). ClC-Kb C-terminal domain
constructs containing the double mutants K604C-A644C and
L603C-H645C both form monodispersed dimers, as observed
with wild-type (data not shown). Unlike the L650C mutant, in
neither case was spontaneous cross-linking observed (Figure 6D).
Moreover, application of H2O2 to catalyze disulfide-bond
formation did not yield cross-links (data not shown). Taken
together, these results suggest that ClC-Kb adopts the same
dimerization interface as ClC-Ka [42].
Discussion
Mutation of residue 538 in the C-terminal cytoplasmic domain
of ClC-Kb gives rise to Bartter’s syndrome [7]. Although the
mechanism by which the disease is caused is unknown, we
hypothesized based on this residue’s location in the cytoplasmic
domain that it may affect function. Indeed, ClC-Kb-R538P
exhibits slightly altered bromide permeability relative to wild type,
indicating that the mutation induces a change in the permeation
pathway. Strikingly, R538P removes extracellular calcium activa-
tion. Extracellular calcium activation must result in a conforma-
tional change that is transmitted from the calcium binding site to
the pore. In order for R538P to abolish the activation, it must
prevent calcium from binding or disrupt the calcium induced
conformational change being transmitted to the pore.
It is not known whether any of the functional changes observed
in ClC-Kb-R538P are related to the Bartter’s Syndrome
phenotype reported by Konrad et al [7]. ClC-Kb is expressed in
the basolateral membrane of kidney epithelia where the
membrane potential is around 270 mV. While ClC-Kb-R538P
exhibits a greater degree of inward rectification compared to wild
type, the current-voltage plots show that deviation from wild type
behavior is minimal at 270 mV (Figure 2). At the normal
basolateral membrane potential, it is not likely that the change in
voltage-dependence observed in ClC-Kb-R538P could alone be
responsible for the disease phenotype.
The disruption in Ca
2+ dependence may be responsible for the
Bartter’s syndrome caused by the R538P mutation. Although not
definitive, there are several reports in the literature that support this
hypothesis. Ca
2+ levels are known to affect chloride transport in the
thin ascending limb [53], and in vivo studies of rat kidney have
revealed variations in interstitial Ca
2+ of about 1 mM [54], in the
range where ClC-Kb activity is affected. Moreover, disruption of
basolateral calcium receptors in the kidney results in Bartter’s-like
symptoms [55,56], which suggests a possible role for calcium
fluctuation in the interstitial spaces in the kidney. Together, these
results suggest that the loss of Ca
2+ activation in the ClC-Kb R538P
mutant may be responsible for the disease. Nevertheless, there are
Figure 3. R538P abolishes calcium activation in hClC-Kb. Current
recordings for (A) wild type and (B) R538P ClC-Kb channels at 0.1 mM
calcium (left) and 10.0 mM calcium (right). (C) Calcium dependent
activation of wild type (filled squares) and R538P (open squares) channels.
Steady-state current levels at +60 mV plotted as a function of [Ca
2+],
normalizedto the value at0.1 mM calcium. Eachdata point is the average
of several (n=4–6) oocytes and error bars show the s.e.m. Only oocytes
that showed reversibility were included in the analysis.
doi:10.1371/journal.pone.0002746.g003
Figure 4. Expression of hClC-Ka-R538P. Two-electrode voltage
clamp current recordings of wild type (A) and R538P (B) expressing
channels. Currents are in response to a 100-ms prepulse to +60 mV follow
by 500-ms test pulses ranging from +60 mV to 2140 mV in 220 mV
steps. (C) Relative permeability ratios for ClC-Ka wild type (filled bars) and
R538P (open bars) channels. The iodide/chloride permeability ratio of
R538P is statistically different from that of wild type (p,0.02, n=3 (WT)
and n=5 (R538P)). (D) Calcium dependence at +60 mV of wild type (open
squares) and R538P (open triangles) normalized to the current at +60 mV
in the presence of 0.1 mM calcium, as in Figure 3. Error bars for WT (n=4)
and R538P (n=3) are the s.e.m.
doi:10.1371/journal.pone.0002746.g004
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R538P does not traffic properly to the basolateral membrane or that
the single-channel conductance is significantly altered, either of
which could lead to altered basolateral chloride conductance. When
equal amounts of wild-type and mutant ClC-Kb RNA are injected
into the same batch of oocytes, there is only a modest (,50%)
difference between wild-type and mutant currents levels (in low
Ca
2+). This suggests that expression level, trafficking, and single-
channel conductance are similar. However, it is still possible that
such a small difference could be responsible for the disease
phenotype. Additionally, it is possible that the difference in
expression or trafficking is even greater in the native tissue, and so
further studies are necessary to determine the cause of the disease.
CLC C-terminal cytoplasmic domains are required for CLC
channel function [24,26–28]. Numerous missense mutations and
truncations in these domains result in disease, with many of the
mutations occurring in the CBSDs [8,57,58]. CBSDs occur in a
wide variety of functionally unrelated proteins. As observed in the
CLCs, mutations in CBSDs in some of these other proteins lead to
disease [39]. In all cases where CBSDs are known to regulate
protein function, the CBSDs are structurally distant from the
catalytic domain of the proteins (for CLCs, the chloride
permeation pathway). Hence, there must be a mechanism for
changes in CBSDs to be passed along to the catalytic domain of
the proteins to which they are attached.
Surprisingly, we did not observe any changes in calcium
activation when R538P was introduced into ClC-Ka. This was
surprising, since the ClC-Ka and ClC-Kb channels are very
similar (,90% identical). One possible explanation for the
different behaviors is that the structures of the ClC-Ka and ClC-
Kb cytoplasmic domains are significantly different, despite their
sequence similarity. Supporting this hypothesis is the observation
that the majority of amino acids in ClC-Kb that differ from ClC-
Ka occur in the residues that would form the two potential
Figure 6. Conserved dimerization interface in the ClC-Kb C-
terminal domain. (A) Stereo view of TM0935 structure (1O50), a
CBSD-containing protein that adopts an alternate dimer interface.
Amino acids corresponding to residues that differ between ClC-Ka and
ClC-Kb are shown in spacefill. The residue corresponding to 636 in ClC-
Kb (see Figure 5A) is shown in black. (B) Residues chosen for cross-
linking studies mapped onto the ClC-Ka C-terminal domain structure:
L650 (black), 603 (cyan), 604 (green), 644 (olive), 645 (magenta). For this
dimer interface, the L650C mutant is expected to form an intersubunit
cross-link. (C) Residues chosen for cross-linking studies mapped onto
the TM0935 structure; color scheme as in B. For this dimer interface, the
603–645 and the 604–644 cysteine double mutants are expected to
form intersubunit cross-links. (D) SDS-PAGE of purified ClC-Kb C-
terminal domains with different cysteine mutations in reducing (2) and
oxidizing (+) conditions.
doi:10.1371/journal.pone.0002746.g006
Figure 5. Dimerization of the ClC-Kb C-terminal domain. (A)
Stereo view of the ClC-Ka cytoplasmic domain structure (2PFI) with
amino acid differences between ClC-Ka and ClC-Kb shown in space fill.
Amino acid F636 (shown in black) is on the dimer interface in ClC-Ka
and when mutated to aspartic acid removes ClC-Ka dimerization. In ClC-
Kb this residue is the non-polar residue serine. (B) Gel filtration
combined with multi-angle light scattering shows that the C-terminal
domain of ClC-Kb forms a dimer in solution. The solid line represents
the absorbance at 280 nm as a function of elution volume. Filled circles
represent the calculated mass at the different elution volumes. The
molar mass was determined to be 37 kDa, consistent with dimerization.
doi:10.1371/journal.pone.0002746.g005
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ClC-Ka C-terminal domain structure and that observed in the
prokaryotic CBSD protein TM0935). However, our cross-linking
studies indicate that dimer conformation adopted by the ClC-Kb
C-terminal domain is that observed in the ClC-Ka structure rather
than that of TM0935 and other proteins. Hence the mechanism
by which the R538P mutation abolishes Ca
2+ activation is not
likely to involve changes in the dimer interface.
The location of amino acid 538 suggests possible mechanisms by
which such a large conformational change can be transmitted
through the membrane domain. Helix-R may extend up to or
beyond position 538, and the introduction of a proline may result in
helix instability (bend or break) that results in a loss of
communication between this helix and the pore/extracellular
domain. It is also possible that R538P disrupts a direct interaction
with the membrane domain or other amino acids in the
cytoplasmic domain (either the N-terminus or C-terminus). Testing
these hypotheses will require structural studies on full-length
protein.
Materials and Methods
Molecular biology
Human ClC-Ka, ClC-Kb and Barttin were subcloned into the
HindIII and EcoRI sites of psGEM. psGEM constructs were
linearized with NheI and transcribed using mMessage T7
transcription kit (Ambion). ClC-Kb cytoplasmic-domain con-
structs containing amino acids 538–684 were inserted into the
EcorR1 and XbaI sites of the pMAL-c2x vector (NEB) to form a
C-terminal fusion protein with maltose-binding protein. All
mutations were generated using PCR based site-directed
mutagenesis.
Electrophysiology
Defolliculated Xenopus oocytes were injected with 55.6 nL of a
2:1 mixture of ClC-Kb:Barttin-Y98A RNA at 550 ng/mLo r
27.5 nL of a 2:1 mixture of ClC-Ka:Bartin-Y98A RNA at 5–
550 ng/mL. (For these studies, the point mutation Y98A in
Barttin, which increases surface expression of ClC-K channels
[59], was used.) Oocytes were incubated at 17uC for 1–7 days
before recording using two-electrode voltage clamp. Electrodes
were pulled to 0.4–1.6 MV and filled with 3 M KCl, 1.6 mM
EGTA, 5 mM HEPES, pH 6.5. The standard bath solution was
96 mM NaCl, 1.8 mM CaCl2, 2 mM KCl, 1 mM MgCl2, and
5 mM Tris-Cl at pH 8.4. For selectivity experiments, 80 mM
chloride was replaced with the indicated anion. Statistical
significance was determined using a student t-test. For calcium
experiments, CaCl2 was excluded and calcium acetate was added
to reach the desired calcium concentration.
Expression and purification of ClC-Kb cytoplasmic
domains
ClC-Kb cytoplasmic domains were expressed as C-terminal
maltose-binding protein fusions (MBP-KbC). E. coli transformed
with MBP-KbC were grown at 37uC in LB media to OD600 of
,0.5, transferred to 25uC, induced with 0.3 mM IPTG, and
grown for 5 additional hours. Cells were harvested by centrifu-
gation, and pellets were suspended in 50 mL storage buffer
(200 mM NaCl, 20 mM Tris-Cl pH 7.4, 1 mM EDTA, 20%
glycerol) and frozen overnight or stored at 220uC. Cells were
thawed and lysed by sonication after application of protease
inhibitor cocktail. Cell lysates were centrifuged for 609 @
96,0006g. The supernatant was loaded onto an amylose column
(NEB), equilibrated with column buffer (200 mM NaCl, 20 mM
Tris-Cl pH 7.4, 1 mM EDTA), and protein was eluted with
10 mM maltose in column buffer. MBP-KbC fusion was digested
with Factor Xa overnight at 4uC (8–10 hours). The digestion
reaction was diluted 106 into cation-exchange buffer A (6 mM
NaCl, 20 mM sodium phosphate, pH 6.0) and loaded onto a
POROS strong cation-exchange column (Applied Biosystems).
After washing away MBP with cation-exchange buffer B (25 mM
NaCl, 20 mM sodium phosphate pH 6.0), purified ClC-Kb C-
terminal domain (KbC) was eluted with a 25 mM to 500 mM
NaCl gradient (in sodium phosphate, pH 6.0).
For cysteine cross-linking experiments, purified KbC was buffer
exchanged (using gel-filtration chromatography) into TBS7.5
(200 mM NaCl, 10 mM Tris pH 7.5, 5 mM ß-mercaptoethanol).
Samples were reduced with 250 mM ß-mercaptoethanol.
Multiangle light scattering
A Shodex PROTEIN KW-802.5 size exclusion chromatography
column, equilibrated with running buffer (200 mM NaCl, 20 mM
Tris-Cl, pH 7.5) was coupled with in-line DAWN EOS multiangle
light scattering, refractive index (Wyatt Technology Corporation)
and UV (Jasco Corporation) detectors (SEC-MALLS). Monomeric
bovine serum albumin at 1 mg/mL was used to calibrate light
scattering detectors. Protein at 1 mg/mL was run through the size
exclusion column at room temperature (23uC). The molecular
weight of the elutedspecies wascalculated using theASTRA 4.90.08
software provided by Wyatt Technology Corporation.
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